The Outlook for Controlled Substances in 2025
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
The Outlook for Controlled Substances in 2025
-
Lu par :
-
De :
À propos de ce contenu audio
On this episode of Ropes & Gray’s podcast series Controlling Opinions, life sciences regulatory and compliance partner Josh Oyster and counsel Beth Weinman are joined by health care partner Brett Friedman and litigation and enforcement partner Andrew O’Connor to discuss what’s to come in 2025 under the new Trump administration on key issues relating to controlled substances. The discussion covers:
- The DEA’s potential rescheduling of cannabis and the ongoing administrative hearing process.
- Updates on telemedicine flexibilities for prescribing controlled substances, including new rules and proposed regulations.
- Latest enforcement developments from the DOJ related to controlled substance prescribing via telemedicine, including notable cases and implications for the future.
Tune in for an insightful conversation on these critical topics and stay informed about the latest legal and regulatory changes in the life sciences and health care industries.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
Aucun commentaire pour le moment
